AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors

Léna Carmès (1, 2) , Guillaume Bort (3, 4, 1) , François Lux (1, 5) , Léa Seban (6) , Paul Rocchi (1, 2) , Zeinaf Muradova (6) , Agnès Hagège (7) , Laurence Heinrich-Balard (8) , Frédéric Delolme (9) , Virginie Gueguen-Chaignon (9) , Charles Truillet (10) , Stephanie Crowley (11) , Elisa Bello (11) , Tristan Doussineau (12) , Michael Dougan (13) , Olivier Tillement (1) , Jonathan Schoenfeld (14) , Needa Brown (15, 16) , Ross Berbeco (15)

1 iLM - FENNEC - iLM - Formation, élaboration de nanomatériaux et cristaux
2 NH TherAguix SA [Meylan]
3 Institut Curie [Paris]
4 CMBC - Chimie et modélisation pour la biologie du cancer
5 IUF - Institut universitaire de France
6 Dana-Farber Cancer Institute [Boston]
7 TechSep - ISA-Separative Methods - Techniques séparatives
8 MATEIS - Matériaux, ingénierie et science [Villeurbanne]
9 SFR Biosciences
10 BIOMAPS - LaBoratoire d'Imagerie biOmédicale MultimodAle Paris-Saclay
11 Whitehead Institute
12 NHTheraguix [Crolles]
13 Massachusetts General Hospital [Boston, MA, USA]
14 Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School
15 Brigham and Women’s Hospital [Boston, MA]
16 Northeastern University [Boston]

Comparison of click chemistry and sortagging grafting strategies for functionalizing AGuIX nanoparticles with nanobodies to develop a tri-functional technology combining MRI imaging, radiotherapy, and immunotherapy by inhibiting immune checkpoints.

Domaines: Chimie; Sciences du Vivant [q-bio]; Cancer

Léna Carmès, Guillaume Bort, François Lux, Léa Seban, Paul Rocchi, et al.. AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors. Nanoscale, 2024, ⟨10.1039/D3NR04777F⟩. ⟨hal-04370969⟩